Serum Institute to Produce Trial Ebola Vaccine Using Oxford‑AstraZeneca Technology

The Serum Institute announced plans to manufacture a trial Ebola vaccine. The vaccine will use technology created by Oxford‑AstraZeneca. The effort highlights the institute’s involvement in vaccine research. The trial vaccine is intended for early testing phases. No specific timeline for development was disclosed. The announcement was reported by NewsBytes. The collaboration reflects ongoing interest in Ebola countermeasures. Observers will watch for further updates on the trial.